Desperate patients get early access to experimental muscle cell therapy

NCT ID NCT04661293

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: Cook MyoSite Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program offers expanded access to an experimental treatment using a patient's own muscle cells. It is for people with serious or life-threatening conditions who have no other options. Doctors can request the treatment for eligible patients, but it is not yet proven to work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

autologous muscle derived cells (AMDCs)

What this could lead to

If successful, this program could provide a treatment option for patients with serious muscle-related diseases who have no other alternatives.

What could go wrong

This is an early expanded access program, not a full clinical trial. The treatment is still investigational, and benefits are not guaranteed. Risks are not fully known.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new related studies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cook MyoSite, Inc.

    Pittsburgh, Pennsylvania, 15238, United States